<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><description>世事洞明皆学问，人情练达即文章</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 25 Feb 2021 11:56:42 +0800</pubDate><image><url>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</url><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>Nature：人类疫苗史上的20项重大里程碑</title><link>https://mp.weixin.qq.com/s/l4j4UftGX12tCMvJ199GQw</link><description></description><content:encoded><![CDATA[Nature：人类疫苗史上的20项重大里程碑]]></content:encoded><pubDate>Thu, 25 Feb 2021 08:02:08 +0800</pubDate></item><item><title>2020年，全球最畅销肿瘤药TOP30</title><link>https://mp.weixin.qq.com/s/DiaGggF8Q_PkxqzWTkTflQ</link><description></description><content:encoded><![CDATA[2020年，全球最畅销肿瘤药TOP30]]></content:encoded><pubDate>Thu, 25 Feb 2021 08:02:08 +0800</pubDate></item><item><title>药欣生物引进凯泰资本近亿元B1轮融资</title><link>https://mp.weixin.qq.com/s/9r8Xypcj9dZJ7dhSN4k9oA</link><description></description><content:encoded><![CDATA[药欣生物引进凯泰资本近亿元B1轮融资]]></content:encoded><pubDate>Thu, 25 Feb 2021 08:02:08 +0800</pubDate></item><item><title>2020年，全球肿瘤药巨头排名TOP10</title><link>https://mp.weixin.qq.com/s/xTM_BWqCgvup4_LaxEBbnw</link><description></description><content:encoded><![CDATA[2020年，全球肿瘤药巨头排名TOP10]]></content:encoded><pubDate>Wed, 24 Feb 2021 07:36:11 +0800</pubDate></item><item><title>三叶草生物完成2.3亿美元C轮融资并获超额募集</title><link>https://mp.weixin.qq.com/s/5ZggrHka3A9nLI44GcOhKA</link><description></description><content:encoded><![CDATA[三叶草生物完成2.3亿美元C轮融资并获超额募集]]></content:encoded><pubDate>Wed, 24 Feb 2021 07:36:11 +0800</pubDate></item><item><title>德琪医药Selinexor新药上市申请获国家药品监督管理局优先审评</title><link>https://mp.weixin.qq.com/s/2qOA-Grez7avTGCTzP2MWA</link><description></description><content:encoded><![CDATA[德琪医药Selinexor新药上市申请获国家药品监督管理局优先审评]]></content:encoded><pubDate>Wed, 24 Feb 2021 07:36:11 +0800</pubDate></item><item><title>医药魔方招聘：EBM/HEOR Research Manager / Senior Manage、药物经济分析师、药物经济实习生</title><link>https://mp.weixin.qq.com/s/Hk3QLK67qt8XwlzPz7Uidw</link><description></description><content:encoded><![CDATA[医药魔方招聘：EBM/HEOR Research Manager / Senior Manage、药物经济分析师、药物经济实习生]]></content:encoded><pubDate>Wed, 24 Feb 2021 07:36:11 +0800</pubDate></item><item><title>阿斯利康撤回Imfinzi膀胱癌适应证美国上市资格</title><link>https://mp.weixin.qq.com/s/LYHn9OQtN0vtSd0mQJa_iw</link><description></description><content:encoded><![CDATA[阿斯利康撤回Imfinzi膀胱癌适应证美国上市资格]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:36:04 +0800</pubDate></item><item><title>中国首个生物类似药获批2周年记：9款产品上市，12份《指导原则》出台，集采渐近</title><link>https://mp.weixin.qq.com/s/dENY9iDw5wUqLS8wbnV2CA</link><description></description><content:encoded><![CDATA[中国首个生物类似药获批2周年记：9款产品上市，12份《指导原则》出台，集采渐近]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:36:04 +0800</pubDate></item><item><title>CDE拟突破性疗法认定：Apollomics/浦润奥c-Met抑制剂治疗NSCLC</title><link>https://mp.weixin.qq.com/s/FU2y9vop-MsUsoXHTs2QEw</link><description></description><content:encoded><![CDATA[CDE拟突破性疗法认定：Apollomics/浦润奥c-Met抑制剂治疗NSCLC]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:36:04 +0800</pubDate></item><item><title>首个PD-L1+MEK联合疗法用于三阴乳腺癌失败：多情却被无情扰？</title><link>https://mp.weixin.qq.com/s/3F9qoZ31rsjAbqAcXFPl2g</link><description></description><content:encoded><![CDATA[首个PD-L1+MEK联合疗法用于三阴乳腺癌失败：多情却被无情扰？]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:36:04 +0800</pubDate></item><item><title>医药魔方招聘：数据分析师（医药大数据方向）、药品数据实习生</title><link>https://mp.weixin.qq.com/s/0WeoKLhceQvaRlrK4Q2TSQ</link><description></description><content:encoded><![CDATA[医药魔方招聘：数据分析师（医药大数据方向）、药品数据实习生]]></content:encoded><pubDate>Tue, 23 Feb 2021 07:36:04 +0800</pubDate></item><item><title>2020年全球制药巨头自身免疫疾病业务排名TOP10</title><link>https://mp.weixin.qq.com/s/7bi2fhao6oZ7lo247vPs7A</link><description></description><content:encoded><![CDATA[2020年全球制药巨头自身免疫疾病业务排名TOP10]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:43:23 +0800</pubDate></item><item><title>制药巨头群雄逐鹿：从AI到量子计算，药物研发快车道蓄势待发</title><link>https://mp.weixin.qq.com/s/374eAMOKZJoJjbcBnJSE6w</link><description></description><content:encoded><![CDATA[制药巨头群雄逐鹿：从AI到量子计算，药物研发快车道蓄势待发]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:43:23 +0800</pubDate></item><item><title>医药魔方招聘：专利专员</title><link>https://mp.weixin.qq.com/s/BDx7PV_sQ0u1rF-ZML2_iA</link><description></description><content:encoded><![CDATA[医药魔方招聘：专利专员]]></content:encoded><pubDate>Mon, 22 Feb 2021 07:43:23 +0800</pubDate></item><item><title>生物分析专栏｜吸入制剂的药代动力学和生物分析</title><link>https://mp.weixin.qq.com/s/d0rWPI5MnG4ZJy8sKNO2aA</link><description></description><content:encoded><![CDATA[生物分析专栏｜吸入制剂的药代动力学和生物分析]]></content:encoded><pubDate>Sun, 21 Feb 2021 08:38:58 +0800</pubDate></item><item><title>生物药，带量采购逼近</title><link>https://mp.weixin.qq.com/s/FlWhB70JzP-D6ku9flIKjA</link><description></description><content:encoded><![CDATA[生物药，带量采购逼近]]></content:encoded><pubDate>Sat, 20 Feb 2021 07:45:35 +0800</pubDate></item><item><title>TCR双特异性蛋白获FDA突破性疗法认定！有望成为40年来首款葡萄膜黑色素瘤新疗法</title><link>https://mp.weixin.qq.com/s/U-FVVsdIv1ytEZkLa7cpMQ</link><description></description><content:encoded><![CDATA[TCR双特异性蛋白获FDA突破性疗法认定！有望成为40年来首款葡萄膜黑色素瘤新疗法]]></content:encoded><pubDate>Sat, 20 Feb 2021 07:45:35 +0800</pubDate></item><item><title>首个人体试验II期临床结果公布！粪菌移植成功逆转癌症患者对PD-1抗体的应答 | Science</title><link>https://mp.weixin.qq.com/s/fdIfJUgtWRcDvoSq4CkPLw</link><description></description><content:encoded><![CDATA[首个人体试验II期临床结果公布！粪菌移植成功逆转癌症患者对PD-1抗体的应答 | Science]]></content:encoded><pubDate>Sat, 20 Feb 2021 07:45:35 +0800</pubDate></item><item><title>医药魔方招聘：咨询分析师、咨询顾问</title><link>https://mp.weixin.qq.com/s/LTMcEVbNN-9eboEOdn8Z5Q</link><description></description><content:encoded><![CDATA[医药魔方招聘：咨询分析师、咨询顾问]]></content:encoded><pubDate>Sat, 20 Feb 2021 07:45:35 +0800</pubDate></item></channel></rss>